Mind Medicine (MindMed), Inc. (MNMD)

NASDAQ: MNMD · IEX Real-Time Price · USD
0.874
0.076 (9.48%)
At close: May 27, 2022 4:00 PM
0.878
0.004 (0.423%)
After-hours:May 27, 2022 7:59 PM EDT

Company Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MindMed), Inc.
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealth Care
Employees41

Contact Details

Address:
1055 West Hastings Street
Vancouver, BC V6E 2E9
Canada
Phone650 208 2454

Stock Details

Ticker SymbolMNMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001813814

Key Executives

NamePosition
Robert BarrowChief Executive Officer and Director
Dr. Miriam Halperin Wernli Ph.D.Executive President and Director
Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer
Dr. Scott M. FreemanCo-Founder and Clinical Advisor
Leonard LatchmanCo-founder
Carrie F. Liao CPA, CGMAVice President, Corporate Controller and Accounting Principal
Wong Hu J.D.Chief Legal Officer and Corporate Secretary
Dr. Francois P. Lilienthal M.B.A., M.D.Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
May 26, 20224Statement of changes in beneficial ownership of securities
May 26, 20224Statement of changes in beneficial ownership of securities
May 24, 20224Statement of changes in beneficial ownership of securities
May 23, 20224Statement of changes in beneficial ownership of securities
May 23, 20223Initial statement of beneficial ownership of securities
May 23, 20228-KCurrent report
May 19, 20224/AStatement of changes in beneficial ownership of securities
May 19, 20228-KCurrent report
May 17, 20224Statement of changes in beneficial ownership of securities
May 20, 2022EFFECTNotice of Effectiveness
View All SEC Filings